JP2019206582A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019206582A5 JP2019206582A5 JP2019147451A JP2019147451A JP2019206582A5 JP 2019206582 A5 JP2019206582 A5 JP 2019206582A5 JP 2019147451 A JP2019147451 A JP 2019147451A JP 2019147451 A JP2019147451 A JP 2019147451A JP 2019206582 A5 JP2019206582 A5 JP 2019206582A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- substitution
- clostridial toxin
- residue
- modified
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 231100001102 clostridial toxin Toxicity 0.000 claims 27
- 238000006467 substitution reaction Methods 0.000 claims 25
- 125000003275 alpha amino acid group Chemical group 0.000 claims 19
- 235000001014 amino acid Nutrition 0.000 claims 19
- 150000007523 nucleic acids Chemical group 0.000 claims 13
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 11
- 108030001720 Bontoxilysin Proteins 0.000 claims 10
- 229940024606 amino acid Drugs 0.000 claims 10
- 150000001413 amino acids Chemical class 0.000 claims 10
- 229940053031 botulinum toxin Drugs 0.000 claims 9
- -1 D546 Substances 0.000 claims 8
- 125000000539 amino acid group Chemical group 0.000 claims 7
- 239000004475 Arginine Substances 0.000 claims 5
- 208000014094 Dystonic disease Diseases 0.000 claims 5
- 239000004472 Lysine Substances 0.000 claims 5
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 5
- 208000004350 Strabismus Diseases 0.000 claims 5
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 5
- 239000010451 perlite Substances 0.000 claims 5
- 239000004144 Ethoxylated Mono- and Di-Glyceride Substances 0.000 claims 4
- 208000008238 Muscle Spasticity Diseases 0.000 claims 4
- 208000010118 dystonia Diseases 0.000 claims 4
- 235000013922 glutamic acid Nutrition 0.000 claims 4
- 239000004220 glutamic acid Substances 0.000 claims 4
- 235000018102 proteins Nutrition 0.000 claims 4
- 102000004169 proteins and genes Human genes 0.000 claims 4
- 108090000623 proteins and genes Proteins 0.000 claims 4
- 239000001587 sorbitan monostearate Substances 0.000 claims 4
- 235000011076 sorbitan monostearate Nutrition 0.000 claims 4
- 208000018198 spasticity Diseases 0.000 claims 4
- 239000001836 Dioctyl sodium sulphosuccinate Substances 0.000 claims 3
- 208000007101 Muscle Cramp Diseases 0.000 claims 3
- 239000004111 Potassium silicate Substances 0.000 claims 3
- 239000004141 Sodium laurylsulphate Substances 0.000 claims 3
- 206010044074 Torticollis Diseases 0.000 claims 3
- 206010005159 blepharospasm Diseases 0.000 claims 3
- 230000000744 blepharospasm Effects 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 229920001184 polypeptide Polymers 0.000 claims 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims 3
- 230000001148 spastic effect Effects 0.000 claims 3
- 101710117542 Botulinum neurotoxin type A Proteins 0.000 claims 2
- 239000001884 Cassia gum Substances 0.000 claims 2
- 239000002656 Distearyl thiodipropionate Substances 0.000 claims 2
- 208000029578 Muscle disease Diseases 0.000 claims 2
- 208000002193 Pain Diseases 0.000 claims 2
- 239000004237 Ponceau 6R Substances 0.000 claims 2
- 101100052669 Schizosaccharomyces pombe (strain 972 / ATCC 24843) N118 gene Proteins 0.000 claims 2
- 206010043118 Tardive Dyskinesia Diseases 0.000 claims 2
- 206010043269 Tension headache Diseases 0.000 claims 2
- 208000008548 Tension-Type Headache Diseases 0.000 claims 2
- 108010055044 Tetanus Toxin Proteins 0.000 claims 2
- 206010044565 Tremor Diseases 0.000 claims 2
- 230000002159 abnormal effect Effects 0.000 claims 2
- 239000000440 bentonite Substances 0.000 claims 2
- 206010006514 bruxism Diseases 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- 239000002537 cosmetic Substances 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000004174 erythrosine Substances 0.000 claims 2
- 208000018197 inherited torticollis Diseases 0.000 claims 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L magnesium sulphate Substances [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 210000003205 muscle Anatomy 0.000 claims 2
- 210000005036 nerve Anatomy 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 239000000264 sodium ferrocyanide Substances 0.000 claims 2
- 239000004324 sodium propionate Substances 0.000 claims 2
- 239000001433 sodium tartrate Substances 0.000 claims 2
- 239000001589 sorbitan tristearate Substances 0.000 claims 2
- 235000011078 sorbitan tristearate Nutrition 0.000 claims 2
- 229940118376 tetanus toxin Drugs 0.000 claims 2
- 230000037303 wrinkles Effects 0.000 claims 2
- 239000001904 Arabinogalactan Substances 0.000 claims 1
- 239000001878 Bakers yeast glycan Substances 0.000 claims 1
- 101710117515 Botulinum neurotoxin type E Proteins 0.000 claims 1
- 101710117520 Botulinum neurotoxin type F Proteins 0.000 claims 1
- 239000001736 Calcium glycerylphosphate Substances 0.000 claims 1
- 239000004140 Calcium stearoyl fumarate Substances 0.000 claims 1
- 101000933563 Clostridium botulinum Botulinum neurotoxin type G Proteins 0.000 claims 1
- 101000985023 Clostridium botulinum C phage Botulinum neurotoxin type C Proteins 0.000 claims 1
- 101000985020 Clostridium botulinum D phage Botulinum neurotoxin type D Proteins 0.000 claims 1
- 206010010904 Convulsion Diseases 0.000 claims 1
- 208000019505 Deglutition disease Diseases 0.000 claims 1
- 208000000289 Esophageal Achalasia Diseases 0.000 claims 1
- 206010063006 Facial spasm Diseases 0.000 claims 1
- 239000004230 Fast Yellow AB Substances 0.000 claims 1
- 206010019233 Headaches Diseases 0.000 claims 1
- 208000004095 Hemifacial Spasm Diseases 0.000 claims 1
- 208000002972 Hepatolenticular Degeneration Diseases 0.000 claims 1
- 208000008454 Hyperhidrosis Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 206010023644 Lacrimation increased Diseases 0.000 claims 1
- 208000021642 Muscular disease Diseases 0.000 claims 1
- 208000000112 Myalgia Diseases 0.000 claims 1
- 208000002033 Myoclonus Diseases 0.000 claims 1
- 239000004118 Natrolite-phonolite Substances 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 239000004396 Octenyl succinic acid modified gum arabic Substances 0.000 claims 1
- 206010030136 Oesophageal achalasia Diseases 0.000 claims 1
- 206010033799 Paralysis Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000036496 Pelvic floor dyssynergia Diseases 0.000 claims 1
- 108091005804 Peptidases Proteins 0.000 claims 1
- 239000004365 Protease Substances 0.000 claims 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 1
- 206010039424 Salivary hypersecretion Diseases 0.000 claims 1
- 206010040954 Skin wrinkling Diseases 0.000 claims 1
- 239000004139 Sodium stearoyl fumarate Substances 0.000 claims 1
- 239000001882 Soybean hemicellulose Substances 0.000 claims 1
- 208000005392 Spasm Diseases 0.000 claims 1
- 206010067672 Spasmodic dysphonia Diseases 0.000 claims 1
- 201000010829 Spina bifida Diseases 0.000 claims 1
- 208000006097 Spinal Dysraphism Diseases 0.000 claims 1
- 239000004138 Stearyl citrate Substances 0.000 claims 1
- 208000003028 Stuttering Diseases 0.000 claims 1
- 102000006275 Ubiquitin-Protein Ligases Human genes 0.000 claims 1
- 108010083111 Ubiquitin-Protein Ligases Proteins 0.000 claims 1
- 208000016599 Uterine disease Diseases 0.000 claims 1
- 208000018839 Wilson disease Diseases 0.000 claims 1
- 208000013142 Writer cramp Diseases 0.000 claims 1
- 201000000621 achalasia Diseases 0.000 claims 1
- 230000002378 acidificating effect Effects 0.000 claims 1
- 230000003213 activating effect Effects 0.000 claims 1
- 239000008272 agar Substances 0.000 claims 1
- 235000010419 agar Nutrition 0.000 claims 1
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 claims 1
- 239000000728 ammonium alginate Substances 0.000 claims 1
- 235000010407 ammonium alginate Nutrition 0.000 claims 1
- 239000000908 ammonium hydroxide Substances 0.000 claims 1
- 201000002898 anismus Diseases 0.000 claims 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 claims 1
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 claims 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N aspartic acid group Chemical group N[C@@H](CC(=O)O)C(=O)O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 1
- 239000000404 calcium aluminium silicate Substances 0.000 claims 1
- 239000004197 calcium inosinate Substances 0.000 claims 1
- 239000000292 calcium oxide Substances 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000000679 carrageenan Substances 0.000 claims 1
- 235000010418 carrageenan Nutrition 0.000 claims 1
- 206010008129 cerebral palsy Diseases 0.000 claims 1
- 201000002866 cervical dystonia Diseases 0.000 claims 1
- 239000001679 citrus red 2 Substances 0.000 claims 1
- 238000003776 cleavage reaction Methods 0.000 claims 1
- 206010009887 colitis Diseases 0.000 claims 1
- 230000036461 convulsion Effects 0.000 claims 1
- 239000001177 diphosphate Substances 0.000 claims 1
- 235000011180 diphosphates Nutrition 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 230000003828 downregulation Effects 0.000 claims 1
- 230000004424 eye movement Effects 0.000 claims 1
- 201000002904 focal dystonia Diseases 0.000 claims 1
- 201000002865 focal hand dystonia Diseases 0.000 claims 1
- 210000001061 forehead Anatomy 0.000 claims 1
- 230000002496 gastric effect Effects 0.000 claims 1
- 239000000216 gellan gum Substances 0.000 claims 1
- 235000010492 gellan gum Nutrition 0.000 claims 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 claims 1
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 claims 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol Substances OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 1
- 235000011187 glycerol Nutrition 0.000 claims 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 claims 1
- 239000004120 green S Substances 0.000 claims 1
- 231100000869 headache Toxicity 0.000 claims 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 claims 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 1
- 230000037315 hyperhidrosis Effects 0.000 claims 1
- 230000002779 inactivation Effects 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 claims 1
- 239000000231 karaya gum Substances 0.000 claims 1
- 235000010494 karaya gum Nutrition 0.000 claims 1
- 230000004317 lacrimation Effects 0.000 claims 1
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 239000000711 locust bean gum Substances 0.000 claims 1
- 235000010420 locust bean gum Nutrition 0.000 claims 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 1
- 230000002934 lysing effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 208000013465 muscle pain Diseases 0.000 claims 1
- 208000018360 neuromuscular disease Diseases 0.000 claims 1
- 206010029864 nystagmus Diseases 0.000 claims 1
- 239000004175 ponceau 4R Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 239000000473 propyl gallate Substances 0.000 claims 1
- 208000026451 salivation Diseases 0.000 claims 1
- 230000007017 scission Effects 0.000 claims 1
- 230000028327 secretion Effects 0.000 claims 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 claims 1
- 210000002460 smooth muscle Anatomy 0.000 claims 1
- 239000004299 sodium benzoate Substances 0.000 claims 1
- 239000004317 sodium nitrate Substances 0.000 claims 1
- 239000001488 sodium phosphate Substances 0.000 claims 1
- 235000019317 soybean hemicellulose Nutrition 0.000 claims 1
- 201000002849 spasmodic dystonia Diseases 0.000 claims 1
- 239000001959 sucrose esters of fatty acids Substances 0.000 claims 1
- 235000010965 sucrose esters of fatty acids Nutrition 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 claims 1
- 210000001685 thyroid gland Anatomy 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 108700012359 toxins Proteins 0.000 claims 1
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019147451A JP6867452B2 (ja) | 2019-08-09 | 2019-08-09 | 陽イオン性神経毒 |
| JP2021063847A JP7328275B2 (ja) | 2019-08-09 | 2021-04-05 | 陽イオン性神経毒 |
| JP2023078304A JP2023090955A (ja) | 2019-08-09 | 2023-05-11 | 陽イオン性神経毒 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019147451A JP6867452B2 (ja) | 2019-08-09 | 2019-08-09 | 陽イオン性神経毒 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017536513A Division JP6601922B2 (ja) | 2015-01-09 | 2015-01-09 | 陽イオン性神経毒 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021063847A Division JP7328275B2 (ja) | 2019-08-09 | 2021-04-05 | 陽イオン性神経毒 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019206582A JP2019206582A (ja) | 2019-12-05 |
| JP2019206582A5 true JP2019206582A5 (enExample) | 2020-05-28 |
| JP6867452B2 JP6867452B2 (ja) | 2021-04-28 |
Family
ID=68768346
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019147451A Active JP6867452B2 (ja) | 2019-08-09 | 2019-08-09 | 陽イオン性神経毒 |
| JP2021063847A Active JP7328275B2 (ja) | 2019-08-09 | 2021-04-05 | 陽イオン性神経毒 |
| JP2023078304A Pending JP2023090955A (ja) | 2019-08-09 | 2023-05-11 | 陽イオン性神経毒 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021063847A Active JP7328275B2 (ja) | 2019-08-09 | 2021-04-05 | 陽イオン性神経毒 |
| JP2023078304A Pending JP2023090955A (ja) | 2019-08-09 | 2023-05-11 | 陽イオン性神経毒 |
Country Status (1)
| Country | Link |
|---|---|
| JP (3) | JP6867452B2 (enExample) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU4746096A (en) * | 1995-06-06 | 1996-12-24 | Wisconsin Alumni Research Foundation | Analogs of botulinum toxin and pharmaceutical compositions o f botulinum toxin |
| US20020127247A1 (en) * | 2000-11-17 | 2002-09-12 | Allergen Sales, Inc. | Modified clostridial neurotoxins with altered biological persistence |
| US7172764B2 (en) * | 2003-11-17 | 2007-02-06 | Allergan, Inc. | Rescue agents for treating botulinum toxin intoxications |
| CA2788074C (en) * | 2010-01-25 | 2016-07-12 | Allergan, Inc. | Methods of intracellular conversion of single-chain proteins into their di-chain form |
-
2019
- 2019-08-09 JP JP2019147451A patent/JP6867452B2/ja active Active
-
2021
- 2021-04-05 JP JP2021063847A patent/JP7328275B2/ja active Active
-
2023
- 2023-05-11 JP JP2023078304A patent/JP2023090955A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018502580A5 (enExample) | ||
| RU2017128211A (ru) | Катионные нейротоксины | |
| Raval et al. | Biochemical and structural characterization of a detergent-stable serine alkaline protease from seawater haloalkaliphilic bacteria | |
| CN111406066B (zh) | 切割非神经元snare的肉毒杆菌神经毒素 | |
| JP6569662B2 (ja) | 新規タンパク質脱アミド酵素 | |
| JP2024012421A5 (enExample) | ||
| JP2018505686A (ja) | 増大したタンパク質発現 | |
| JP2019206582A5 (enExample) | ||
| Qu et al. | The characteristics of protein-glutaminase from an isolated Chryseobacterium cucumeris strain and its deamidation application | |
| Okuda et al. | A new subtilisin family: nucleotide and deduced amino acid sequences of new high-molecular-mass alkaline proteases from Bacillus spp. | |
| JP2013252115A (ja) | 組換え微生物及びそれを用いたポリ−γ−グルタミン酸の製造方法 | |
| CN104619853B (zh) | 多肽表达方法 | |
| JP4839144B2 (ja) | 宿主微生物 | |
| JP7328275B2 (ja) | 陽イオン性神経毒 | |
| Oh et al. | Isolation of bacteria from chunggukjang prepared by rice straw and identification of protease secreted | |
| Hosseini | Isolation, Molecular Cloning, Expression and Bioinformatics Evaluation of aprX Serine Protease Gene Extracted from Bacillus licheniformis | |
| JP4820101B2 (ja) | 変異バチルス属細菌 | |
| JP2023090955A5 (enExample) | ||
| JP4861659B2 (ja) | 組換え微生物 | |
| JP4648038B2 (ja) | 改変プロモーター | |
| JP4839169B2 (ja) | 組換え微生物 | |
| Kim et al. | Heterologous expression and secretion of sweet potato peroxidase isoenzyme A1 in recombinant Saccharomyces cerevisiae | |
| JP2025110393A (ja) | バイオポリマー製造方法 | |
| Gandhi et al. | Research Article Expression and Characterization of Geobacillus stearothermophilus SR74 Recombinant�-Amylase in Pichia pastoris | |
| Liu XuDong et al. | Molecular cloning and characterization of an α-amylase with raw starch digestibility from Bacillus sp. YX-1. |